Cardiff Oncology Inc (CRDF) Reports Q4 and Full Year 2023 Financial Results [Yahoo! Finance]
Cardiff Oncology, Inc. (CRDF)
Company Research
Source: Yahoo! Finance
Operating Expenses : Increased to $45.9 million for the full year 2023, up from $40.3 million in 2022. Net Loss : Reported a net loss of $41.4 million for the full year 2023, compared to a net loss of $38.7 million in 2022. Research and Development : R&D expenses rose to $32.9 million, reflecting investment in clinical programs and development of lead drug candidate, onvansertib. Revenue : Royalty revenues increased slightly to $488,000 in 2023 from $386,000 in 2022. Warning! GuruFocus has detected 7 Warning Signs with CRDF. On February 29, 2024, Cardiff Oncology Inc ( NASDAQ:CRDF ) released its 8-K filing , detailing the financial results for the fourth quarter and the full year ended December 31, 2023, and providing a business update. The clinical-stage biotechnology company, known for developing treatment options for cancer patients, particularly in indications with significant medical needs, has reported several key milestones and financial metrics that are critical for
Show less
Read more
Impact Snapshot
Event Time:
CRDF
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRDF alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRDF alerts
High impacting Cardiff Oncology, Inc. news events
Weekly update
A roundup of the hottest topics
CRDF
News
- Cardiff Oncology, Inc. (NASDAQ:CRDF) Q1 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- Cardiff Oncology Reports First Quarter 2024 Results and Provides Business UpdateGlobeNewswire
- Global PLK Targeted Therapies Market Opportunity & Clinical Trials Insight 2024 - Groundbreaking Advances in PLK Targeted Therapies Promise to Revolutionize Treatment for Cancer and Other Diseases [Yahoo! Finance]Yahoo! Finance
- Cardiff Oncology to Report First Quarter 2024 Results and Provide Business UpdateGlobeNewswire
CRDF
Earnings
- 5/2/24 - Beat
CRDF
Sec Filings
- 5/2/24 - Form 8-K
- 5/2/24 - Form 10-Q
- 4/25/24 - Form DEFA14A
- CRDF's page on the SEC website